InSysBio to participate in World Bispecific Summit 2023

2 1. 02 Jun 2020 13:24 InSysBio to announce the launch of QSP model of COVID-19 The new open source project to be developed and updated Online InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

5 1. 05 Jun 2020 15:04 InSysBio to present IRT Navigator 3 InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.

8 1. 08 Jun 2020 15:30 InSysBio to perform the first step in development of COVID-19 QSP model InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

12 1. 12 Jun 2020 16:45 InSysBio to release the new version of Cytocon DB 1.1.6.4 We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.

17 1. 17 Jun 2020 15:48 InSysBio to welcome its new team member Dr. Neil Benson InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development (Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.

22 1. 22 Jun 2020 17:04 InSysBio team posters to be presented at AACR Virtual Annual Meeting II AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website

30 1. 30 Jun 2020 15:45 InSysBio to present COVID-19 QSP model further development InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

events

Conference

August 16, 2023

August 16, 2023

InSysBio announces its participation in the 14^th Annual World Bispecific Summit which is to be held on October 2-4, 2023 at Boston Park Plaza, Boston, MA. Oleg Demin Jr, Scientific Director, QSP modeling in Oncology & Immuno-Oncology, InSysBio will give a talk in frames of Preclinical & Clinical Track - Optimizing Translation into the Clinic to Maximize Bispecific Therapeutic Indexes.

Tuesday, October 3, 12:30 pm

"Mechanistic Translational PK/RO Modeling vs MABEL to Predict First-in-Human Dose for Bispecific & Multispecific Antibodies"

Oleg Demin Jr will cover the following points:

Minimal Anticipated Biological Effect Level (MABEL) approach is recommended to select clinical starting dose for mAbs and multispecific biotherapeutics.
For many immune-activating antibodies first-in-human (FIH) doses identified by MABEL were low and required many dose escalation steps exposing patients to sub-therapeutic doses.
Mechanistic translational PK/RO modeling predicts FIH dose for multispecific antibodies taking into account specific features of the candidate (affinity, avidity, targets), its concentration in tumor, and mechanism of action (trimers and other complexes in immunological synapse responsible for effect, bell-shaped dose dependence, etc.): a case of HPN536, a T-cell engager targeting mesothelin.

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Edinburgh, UK (INSYSBIO UK LIMITED), Limassol, Cyprus (INSYSBIO CY Ltd) and Moscow, Russia (INSYSBIO LLC). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com

←	June 2020	→
Mo	Tu	We	Th	Fr	Sa	Su
1	2 1. 02 Jun 2020 13:24 InSysBio to announce the launch of QSP model of COVID-19 The new open source project to be developed and updated Online InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.	3	4	5 1. 05 Jun 2020 15:04 InSysBio to present IRT Navigator 3 InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.	6	7
8 1. 08 Jun 2020 15:30 InSysBio to perform the first step in development of COVID-19 QSP model InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.	9	10	11	12 1. 12 Jun 2020 16:45 InSysBio to release the new version of Cytocon DB 1.1.6.4 We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.	13	14
15	16	17 1. 17 Jun 2020 15:48 InSysBio to welcome its new team member Dr. Neil Benson InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development (Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.	18	19	20	21
22 1. 22 Jun 2020 17:04 InSysBio team posters to be presented at AACR Virtual Annual Meeting II AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website	23	24	25	26	27	28
29	30 1. 30 Jun 2020 15:45 InSysBio to present COVID-19 QSP model further development InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

Upcoming Events

10.11

InSysBio to take part in ACoP 2024

06.11

InSysBio to participate in SITC 2024